Sort   by:  
 Page size 
UnknownNew Approaches In Medicaid: Work Requirements, Health Savings Accounts, And Health Care Access.
Not available
S-EPMC6076424 | biostudies-literature
UnknownMedicaid Work Requirements In Arkansas: Two-Year Impacts On Coverage, Employment, And Affordability Of Care.
Not available
S-EPMC7497731 | biostudies-literature
UnknownClinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
Not available
S-EPMC4843946 | biostudies-literature
UnknownRespiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study.
Not available
S-EPMC9469080 | biostudies-literature
UnknownA Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk.
Not available
S-EPMC6105323 | biostudies-literature
UnknownIdentical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes.
Not available
S-EPMC6341285 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8491132 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
Sort   by:  
 Page size